Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zobniw, Chrystia M, Causebrook, Alanna, Fong, Mei Ka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128838/
https://www.ncbi.nlm.nih.gov/pubmed/25157341
http://dx.doi.org/10.2147/RRU.S29003
_version_ 1782330182799982592
author Zobniw, Chrystia M
Causebrook, Alanna
Fong, Mei Ka
author_facet Zobniw, Chrystia M
Causebrook, Alanna
Fong, Mei Ka
author_sort Zobniw, Chrystia M
collection PubMed
description Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
format Online
Article
Text
id pubmed-4128838
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41288382014-08-25 Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer Zobniw, Chrystia M Causebrook, Alanna Fong, Mei Ka Res Rep Urol Review Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer. Dove Medical Press 2014-08-05 /pmc/articles/PMC4128838/ /pubmed/25157341 http://dx.doi.org/10.2147/RRU.S29003 Text en © 2014 Zobniw et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zobniw, Chrystia M
Causebrook, Alanna
Fong, Mei Ka
Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title_full Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title_fullStr Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title_full_unstemmed Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title_short Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
title_sort clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128838/
https://www.ncbi.nlm.nih.gov/pubmed/25157341
http://dx.doi.org/10.2147/RRU.S29003
work_keys_str_mv AT zobniwchrystiam clinicaluseofabirateroneinthetreatmentofmetastaticcastrationresistantprostatecancer
AT causebrookalanna clinicaluseofabirateroneinthetreatmentofmetastaticcastrationresistantprostatecancer
AT fongmeika clinicaluseofabirateroneinthetreatmentofmetastaticcastrationresistantprostatecancer

Ejemplares similares